Endocare delisted from Nasdaq:
This article was originally published in Clinica
Urology diagnostic and device firm Endocare has been delisted from the Nasdaq stock market. Trading in the Irvine, California company's shares had been suspended since December 12. It had failed to provide financial reports, and the situation was exacerbated by its auditor admitting a lack of faith in senior management and the sacking of the chief financial officer (see Clinica No 1039, p 8). Endocare plans to appeal the delisting order, but there is no stay on the decision and trading on the OTC Bulletin Board is also banned because the company has not provided required filings to the Securities and Exchange Commission.